Entecavir (ETV) vs Other Anti-HBV Medication (Non-ETV): Number of Participants With HCC Malignant Neoplasm
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.0386 | 0.0341 | 0.0437 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.0427 | 0.0379 | 0.048 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | -0.00407 | -0.0111 | 0.0029 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 0.905 | 0.762 | 1.07 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 0.901 | 0.753 | 1.08 | log | ClinicalTrials.gov | |
| Number needed to treat, for one fewer participant with the outcome on Entecavir (ETV) than on Other Anti-HBV Medication (Non-ETV) | 246 | from the risk difference interval | the interval includes no difference | ClinicalTrials.gov |
Groups 2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Entecavir (ETV) | Tablets / Oral Solution, Oral, ETV = 0.5 mg - 1 mg, once daily. | 240 | 6,216 | OG000 | ClinicalTrials.gov |
| Group 2 | Other Anti-HBV Medication (Non-ETV) | Standard of care HBV Nucleoside/Nucleotide Monotherapy, specific agent selected at the discretion of the investigator | 263 | 6,162 | OG001 | ClinicalTrials.gov |
Outcome 5
| Field | Value | Source |
|---|---|---|
| Type | SECONDARY | ClinicalTrials.gov |
| Title | Number of Participants With HCC Malignant Neoplasm | ClinicalTrials.gov |
| Description | The number of participants with HCC malignant neoplasm, as adjudicated by Events Adjudication Committee (EAC) | ClinicalTrials.gov |
| Time frame | 10 years | ClinicalTrials.gov |
| Population | All randomized, treated participants | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | Study of Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection | ClinicalTrials.gov |
| NCT number | NCT00388674 | ClinicalTrials.gov |
| Phases | ClinicalTrials.gov | |
| Conditions | Chronic Hepatitis B | ClinicalTrials.gov |
| Interventions | entecavir, Other anti-HBV medication | ClinicalTrials.gov |
| Lead sponsor | Bristol-Myers Squibb | ClinicalTrials.gov |
| Results first posted | 2018-07-30 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT00388674?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.